Indian Journal of Dermatology, Venereology and Leprology

Journal Information
EISSN : 0378-6323
Published by: Scientific Scholar (10.25259)
Total articles ≅ 471
Current Coverage
SCOPUS
SCIE
MEDLINE
PUBMED
Filter:

Latest articles in this journal

Trashita Hassanandani, Maitreyee Panda, Ajaya Kumar Jena,
Indian Journal of Dermatology, Venereology and Leprology pp 1-8; https://doi.org/10.25259/ijdvl_843_2021

Abstract:
Background: Palmoplantar psoriasis is a chronic debilitating condition which significantly impairs quality of life. Objectives: To assess the efficacy and safety of the combination of apremilast and methotrexate compared with methotrexate monotherapy in the treatment of palmoplantar psoriasis. Also, to study the impact on treatment on the Dermatology Life Quality Index and Palmoplantar Quality of Life Index. Methods: A total of 64 patients were randomised to two groups in a 1:1 ratio - Group A received both methotrexate and apremilast in combination, while Group B received only methotrexate, for 16 weeks. The primary endpoints were the mean score of Modified Palmoplantar Psoriasis Area and Severity Index at week 16, the proportion of patients achieving modified palmoplantar psoriasis area severity index-75 and/or Palmoplantar Psoriasis Physician Global Assessment score 0/1 at week 16. Results: A significantly higher proportion of patients in Group A achieved Modified Palmoplantar Psoriasis Area and Severity Index-75 at week 16 (43% in Group A vs 30% in Group B). The Modified Palmoplantar Psoriasis Area and Severity Index score was significantly lower in the combination group at week 16 (4.03 ± 2.05 in Group A and 5.89 ± 2.31 in Group B, P-value = 0.002). About 80% of patients in the combination group with baseline Palmoplantar Psoriasis Physician Global Assessment ≥3 achieved Palmoplantar Psoriasis Physician Global Assessment 0/1 compared to 60% in Group B. The combination group showed a significantly higher reduction in Dermatology Life Quality Index and Palmoplantar Quality of Life Index scores compared to the methotrexate alone group (P-value = 0.025). No notable adverse events were observed. Limitation: The limitations of the study were single blinding, small sample size and a lack of longer follow up to assess the rate of relapse. We did not account for attrition during sample size calculation. Also, due to the paucity of data regarding the use of apremilast in palmoplantar psoriasis, definitive comparisons could not be made with previous studies. Conclusion: The combination of apremilast and methotrexate has superior efficacy and a similar safety profile as compared to methotrexate monotherapy for the treatment of moderate to severe palmoplantar psoriasis.
Maria Clara Cavalcante Espósito, Ana Cláudia Cavalcante Espósito, Felipe Kesrouani Lemos, Marilia Formentini Scotton Jorge, Maria Paula Barbieri D’Elia, Hélio Amante Miot
Indian Journal of Dermatology, Venereology and Leprology pp 1-3; https://doi.org/10.25259/ijdvl_845_2021

Back to Top Top